January 12, 2017

J.P. Morgan 35th Annual Healthcare Conference

Chris Simon CEO

2017 Haemonetics Corporation

 Forward-looking statements and non-GAAP
financial information

This presentation contains forward-looking statements that involve risks and uncertainties which are
detailed in the Companys filings with the Securities and Exchange Commission. The forward looking
statements are based on estimates and assumptions made by management of the Company and are
believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could
differ materially from the forward-looking statements. Please see the Companys 10K for the full
cautionary statement. A copy of the Companys form 10K is available on the Companys website:
www.haemonetics.com
In addition to disclosing financial results in accordance with U.S. generally accepted accounting
principles (GAAP), the Company also discloses supplemental non-GAAP financial information
including elements of operating income, operating income, net income, net income per common share
and free cash flow on an adjusted basis that excludes restructuring costs, contingent consideration
income and asset write downs. Reconciliations between GAAP and adjusted numbers are on the
Companys website: www.haemonetics.com

2 2017 Haemonetics Corporation

 Haemonetics business overview
a historical perspective
NYSE: HAE $860M* revenue $2.1B market cap 51M shares

Plasma Hospital Blood Center

$400M $170M $290M
Strong market fundamentals Hemostasis Management Declining market with challenging
Leading share Large addressable market fundamentals
Leading share Loss of competitive advantage in
Cell Salvage relatively attractive product lines
Lower growth market
Top 2 competitor
Transfusion Management
Sizeable under-penetrated market
Leading share in fragmented market
* First Half FY17 revenue of $430M annualized
3 2017 Haemonetics Corporation
 HAE business portfolio whole greater
than sum of parts

Plasma Hospital Blood Center

High potential for continued growth High potential for accelerated Declining revenue and continued
at enhanced profitability levels growth through market penetration pricing pressures
Success dependent on flawless intro- Significant investment in market Potential to optimize op income
duction of new disruptive technology development required through focus and simplification

Near-term revenue and Accelerated growth at Robust contribution to

profits, longer term ROIC hospital device margins op income and cash flow

Driving productivity to invest in long-term potential

4 2017 Haemonetics Corporation

 Plasma
Exciting potential investment and operational excellence
Potential Investment
Attractive market fundamentals Capacity to meet
(stable, upper single-digit growth) market demand for
disposables
Above market top line growth
(new markets, customers, and Placement of 20K+
pricing) new PCS 300 devices

Increasing margin Refurbishment and

subsequent placement
(more efficient use
of PCS II devices
of resources)

5 2017 Haemonetics Corporation

 Plasma
Attractive opportunity serving growing plasma market
Growing global plasma fractionation
market
Favorable epidemiology
(aging population, disease
incidence) ~$26B
Broader use (expanding ~$19B
indications1)
Increased per patient use
(IVIG SCIG shift)

2016 2021
1 Neurology, Immunology, Hematology, Oncology, Pulmonology, Rheumatology, Critical Care, Others
Source: MarketsAndMarkets Global Plasma Fractionation Market Report (August 2016)
6 2017 Haemonetics Corporation
 Plasma
Substantial incremental value through new offering

Customer value drivers

Nextgen Yield improvement

Donor management
software

Process efficiency
PCS 300
Collection device
Capacity optimization
Value-added
software apps
7 2017 Haemonetics Corporation
 Hospital
Exciting potential, requiring investment
Potential 3 product lines, 1 BU Investment

Leverage capabilities Evidence generation

across product lines
Cell
Hemostasis Cell Cartridge production
Advance commercial Salvage
Management Salvage Sales and account
and operational
management
excellence
Tailored solutions
Accelerate organic Transfusion
growth Management Inorganic growth
Supplement with
inorganic growth
Operating leverage

8 2017 Haemonetics Corporation

 Hospital Hemostasis Management
Invest in our fastest growing Hospital business

TEG 6s shaping standard

of care
Attractive market with long-
term growth potential (in line
with hospital devices)
Investments to drive both
market expansion and share
growth TEG 6s / TEG Manager

9 2017 Haemonetics Corporation

 Hospital Cell Salvage
Revitalizing our largest Hospital product line

Lower growth market

Step-wise innovation
Connectivity driven opportunity
for improved equipment use
Opportunities for share gains 7.0
and geographic expansion
ver. 7.1
Cell
Saver
ver. 7.0

10 2017 Haemonetics Corporation

 Hospital Transfusion Management
Leveraging Patient Blood Management capabilities for growth

Sizeable, underpenetrated BloodTrack / SafeTrace Tx

market Centralized blood supply management
Combined software products Point-of-Care blood storage and access
build on technology core
Solutions provide economic
and clinical benefits to
hospitals and their patients
Opportunities for system wide
improvements in blood
management

11 2017 Haemonetics Corporation

 Blood Center
Structural challenges decrease market attractiveness
Declining blood utilization ~$290M revenue*
(e.g., guidelines, PBM) profitable / significant cash flow

Customers under financial

Whole blood
pressure

Product commoditization Software

and price competition
Apheresis
Competitive pressure in
apheresis technology

Decreasing revenues, but sizeable free cash flow contribution

* First Half FY17 revenue of $145M annualized
12 2017 Haemonetics Corporation
 Blood Center
Managing to preserve profitability / capture value

Stabilize Separate Optimize

Declining revenue Operations footprint Productivity
Manageable mid-single Unique facilities Operations and
digit % commercial costs
Financial statements
Selective new Simplification
Profit measurement
opportunities; ROIC
SKUs, countries
focus Team compensation

Time-bound execution and pursuit of realistic options

13 2017 Haemonetics Corporation
 HAE growth drivers
Each Business Unit will make a distinctive contribution

Plasma
Sustain growth via investment
Long-term ROIC engine

Hospital
Accelerate growth via investment
Long-term return to normal hospital-level
margins

Blood Center
Optimize Op Income via productivity
Maintain Op Income in declining
revenue environment

14 2017 Haemonetics Corporation

 HAE growth drivers
The Corporate Centers distinctive contribution

Plasma Corporate Center roles

Sustain growth via investment
Long-term ROIC engine
Hospital
Accelerate growth via investment
Long-term return to normal hospital-level
margins
Blood Center
Optimize Op Income via productivity
Maintain Op Income in declining
revenue environment
Capital allocation
Talent management
Compliance and governance
Productivity
Facility divestitures
SKU / country rationalization
Rework complex and unfavorable contracts
R&D portfolio rationalization
Clinical trial efficiency improvements
Core process redesign

15 2017 Haemonetics Corporation

 A multi-year turnaround across 3 phases
Stabilize Transform Accelerate growth
Q1-Q2 FY17 Q3 FY17Q4 FY18 FY19 onwards

Sustained productivity by creating a more effective and efficient

business model

Organic growth and new portfolio strategy to maximize value

of each segment

M&A initiated to accelerate growth

Drive organization / talent / culture focused on execution, quality, speed

and entrepreneurialism

16 2017 Haemonetics Corporation

 Med Tech value creation: HAE strategic intent

Compete Achieve a #1 Deliver

in winning or #2 market superior short-
segments and position in term and long-
geographies each segment term operating
(growth, where we performance
profitability) compete (ROIC)

17 2017 Haemonetics Corporation

 Focus areas on journey to value creation
Sustainability Investing in strong, well-positioned products
in attractive, healthy markets
Productivity To free-up resources to invest in promising
growth opportunities HAE
Capital allocation Ensuring unique contribution for each business positioned
to achieve
Synergy The whole can be worth significantly more than sustained,
the sum of the parts
profitable
Inorganic growth To augment growth and improve operating growth
leverage in core franchises
Building It is early days on a long journey, but we are
momentum making good progress

18 2017 Haemonetics Corporation